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Parkinson disease (PD) is a late-onset neurodegenerative disorder. The mean age at onset is 61 years, but the disease
can range from juvenile cases to cases in the 8th or 9th decade of life. The parkin gene on chromosome 6q and
loci on chromosome 1p35-36 and 1p36 are responsible for some cases of autosomal recessive early-onset parkin-
sonism, but they do not appear to influence susceptibility or variability of age at onset for idiopathic PD. We have
performed a genomewide linkage analysis using variance-component methodology to identify genes influencing age
at onset of PD in a population of affected relatives (mainly affected sibling pairs) participating in the GenePD
study. Four chromosomal loci showed suggestive evidence of linkage: chromosome 2p (maximum multipoint LOD
[MaxLOD] p 2.08), chromosome 9q (MaxLODp 2.00), chromosome 20 (MaxLODp 1.82), and chromosome
21 (MaxLODp 2.21). The 2p and 9q locations that we report here have previously been reported as loci influencing
PD affection status. Association between PD age at onset and allele 174 of marker D2S1394, located on 2p13,
was observed in the GenePD sample ( ). This 174 allele is common to the PD haplotype observed in twoPp .02
families that show linkage to PARK3 and have autosomal dominant PD, which suggests that this allele may be in
linkage disequilibrium with a mutation influencing PD susceptibility or age at onset of PD.
Introduction
Parkinson disease (PD [MIM 168600]) is a late-onset
neurodegenerative disorder characterized by resting
tremor, rigidity, slowness of movement, and postural in-
stability. The disorder results from degeneration of neu-
rons within the substantia nigra, creating a deficiency in
dopamine-mediated movement. Although dopamine re-
placement therapy mitigates symptoms andmay increase
longevity, it does not stop disease progression or restore
full quality of life. The etiology of PD is unknown, al-
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though there is evidence to suggest that it is multifac-
torial, involving both genetic susceptibility and environ-
mental agents or traumas.
To date, three genes causing familial forms of PD have
been identified. These include the a-synuclein gene on
4q21-23/PARK1 (MIM 163890; Polymeropoulos et al.
1997) and ubiquitin C-terminal hydrolase on 4p14/
PARK5 (MIM 191342; Leroy et al. 1998), both of
which cause autosomal dominant forms of PD, as well
as parkin on 6q25-27/PARK2 (MIM 602544; Kitada et
al. 1998), which causes early-onset recessive PD. Link-
age studies have identified four chromosomal regions
with evidence for PD-related genes, at 2p13/PARK3
(MIM 602404; Gasser et al. 1998), 4p15/PARK4 (MIM
605543; Farrer et al. 1999), 1p35-p36/PARK6 (MIM
605909; Valente et al. 2001), and 1p36/PARK7 (MIM
606324; van Duijn et al. 2001), but genes have not been
cloned at those locations.
1090 Am. J. Hum. Genet. 70:1089–1095, 2002
Two genome scans evaluating linkage to affection
status in multiplex families with idiopathic PD have
been reported (DeStefano et al. 2001; Scott et al. 2001).
Both studies yielded evidence of linkage to 9q and to
several other regions that did not overlap between the
two scans. Scott et al. (2001) observed significant evi-
dence of linkage to 6q in the region of the parkin gene,
in a subset of families with early-onset PD, but not to
any of the other familial loci. No evidence of linkage
to any familial PD loci was observed by DeStefano et
al. (2001). Although stratification by age at onset was
not performed in that sample, the families were screened
for mutations in the parkin gene, and those with parkin
mutations were excluded from the genome scan. On the
basis of these analyses of linkage to affection status,
there is no evidence that the genes implicated in the rare
Mendelian forms of PD are major susceptibility genes
for common idiopathic PD.
Although previous genetic studies have focused on
affection status as the outcome of interest, there is also
evidence of a genetic influence on age at onset of PD.
A segregation analysis based on 948 consecutively as-
certained PD index cases and a total of 4,351 individ-
uals found the best-fit model to be a major gene with
an additive effect influencing age at onset (Maher et al.,
in press). The estimated gene frequency of this onset-
age or penetrance gene was .02, indicating a rare gene
in the population. There was also evidence for a very
rare (i.e., estimated frequencyp 0.008) dominant gene
influencing PD susceptibility. Evidence of a gene influ-
encing age at onset of PD is important because identi-
fication of such a gene would contribute to the under-
standing of disease development and progression and
could provide new targets for therapy. The ability to
delay the onset of PD by 10 years, for example, could
significantly reduce the impact of this disease. Recently,
increasing attention has been paid to genetic influences
on age at onset and methods to identify such genes (e.g.,
Horvath et al. 2001), particularly for adult-onset neu-
rological disorders (Cardno et al. 2001; Rosenblatt et
al. 2001).
To identify genes influencing age at onset of PD,
we performed a genomewide linkage analysis of age
at onset in a set of 103 multiplex families. Regions
showing evidence of linkage were further examined
using association tests and by genotyping of addi-
tional markers in a larger set of individuals. Follow-
up analyses strengthened the evidence for linkage at
2p.
Subjects and Methods
Subjects
Relative pairs with PDwere ascertained through index
cases at 13 clinical sites. Neurologists from the partic-
ipating sites examined and confirmed the PD diagnosis
for each of the index patients and their affected relatives,
with the exception of two individuals, for whom con-
firmation of diagnosis is ongoing. Diagnostic criteria for
PD were based on the United Kingdom PD Society Brain
Bank Criteria (Gibb and Lees 1988), but we removed
“more than one affected relative” and “repeated head
injury” as exclusionary criteria. In their original form,
these criteria have a positive predictive value of 82%
(Hughes et al. 1992); hence, we considered these mod-
ifications unlikely to degrade the positive predictive
value. All neurologists participated in video-based in-
terrater reliability training to ensure diagnostic consis-
tency. All participants signed a consent form approved
by the human-subjects committee of each participating
institution.
A total of 103 families with multiple individuals with
PD were included in the genome scan. There were 98
sibships of size 2, 3 sibships of size 3, and 1 sibship of
size 4, giving a total of 113 affected full-sib pairs (see
DeStefano et al. 2001). Included in these counts is an
extended pedigree consisting of an affected sib pair with
an unaffected sibling who had three offspring with PD,
creating affected avuncular pairs within the family. Two
families consisted of affected half-sib pairs. In addition,
one affected parent and nine unaffected siblings were
genotyped.
Follow-up studies were conducted in the original scan
families, 49 additional sib pairs, and 1 additional half-
sib pair with onset-age data. A total of 22 parent-off-
spring pairs were genotyped in the expanded sample.
Genotyping
Genomic DNA was extracted from lymphocytes
through use of a Nucleon II DNA extraction kit. The
scan consisted of 339 markers, with an average inter-
marker distance of 11 cM, from the Weber set 8, ob-
tained from Research Genetics. The sib_kin program in
the ASPEX package (The ASPEX Linkage Analysis ftp
site) was used to verify sibling relationships. Pairs re-
ported as full sibs but not confirmed as such were deleted
from subsequent analyses. Mendelian inconsistencies in
the genotype data were identified using Genehunter
(Kruglyak et al. 1996). Genotypes for the entire nuclear
family were deleted for the particular marker that
yielded errors.
Analysis
Linkage analysis of PD affection status in these fam-
ilies, through use of the identical genome-scan genotype
data, has been published elsewhere (DeStefano et al.
2001). The present article presents a novel analysis of
these data through use of age at onset as the phenotype
of interest.
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Figure 1 Multipoint LOD-score curves for variance-component analysis of linkage to PD age at onset for chromosomes 2, 9, 20, and
21. The X-axes represent location in centimorgans, and the Y-axes represent LOD score.
Variance-component linkage analysis of age at onset
was performed using Genehunter 2.1 (Pratt et al. 2000).
Age at onset was known for all individuals with PD.
Unaffected individuals are censored subjects with respect
to age at onset; age at onset was coded as “missing” for
all unaffected individuals. However, genotype informa-
tion was included for nine unaffected siblings, to im-
prove identity-by-descent estimation.
Family-based association tests (FBATs) evaluating as-
sociation between markers and age at onset were con-
ducted using the program FBAT (Laird et al. 2000; FBAT
Web Page). A brief review of the tests implemented in
FBAT is given below. These tests are described in detail
elsewhere (Rabinowitz and Laird 2000; Horvath et al.
2001). A general form of an FBAT statistic for family i
(with ni offspring) is
ni
S p X T ,i ij ij
jp1
where Xij is a function of the genotype data of offspring
j in family i and Tij is a function of the phenotype data
of that offspring. For a biallelic marker, a score statistic
based on Si can be defined as
N [S  E(S )]i iZp , ip1 V(S )i
where and are the mean and variance, re-E(S ) V(S )i i
spectively, of Si under the null hypothesis of no linkage,
and N is the total number of families. If the coding of
Xij specifies an additive model (i.e., Xij p the number
of alleles of interest [0, 1, or 2] carried by offspring j in
family i) and Tij is specified as 0 for unaffected and 1
for affected, then this statistic is equivalent to the trans-
mission/disequilibrium test for genotyped parent-off-
spring trios (Lunetta et al. 2000).
When parental genotypes are available, can beE(S )i
computed by conditioning on the observed traits and
parental marker genotypes and is based on Mendelian
transmission probabilities (see Horvath et al. [2001] for
details). For late-onset diseases such as PD, parental ge-
notype information is often not available and compu-
tation of the null distribution is not straightforward.
Rabinowitz and Laird (2000) invoke the statistical
method of conditioning on sufficient statistics for the
null hypothesis to construct a test of association when
parental genotypes are not available. In this case, the
offspring genotype distribution is defined by condition-
ing on the observed traits, the partially observed parental
genotypes, and the offspring configuration. Tables pre-
senting the conditional probabilities when partial or no
parental genotype information is available are given in
the FBAT technical report portion of the FBAT docu-
mentation. At least two distinct offspring genotypes
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Table 1
Maximum Multipoint and Two-Point LOD Scores and Flanking Markers for
Regions with Multipoint LOD 11.5
CHROMOSOME
TWO-POINT LOD MULTIPOINT LOD
Locationa
(cM) Marker LOD Score
Locationa
(cM) LOD Score
2 91 D2S1394 .50
2 99 D2S1777 2.40 99 2.08
2 114 D2S2972 .36
9 111 D9S938 .46
9 120 D9S930 1.86 116 2.00
9 128 D9S934 .48
20 48 D20S477 .14
20 54 D20S478 .95 54 1.82
20 62 D20S481 .89
21 13 D21S1437 .39
21 24 D21S2052 .94 32 2.21
21 37 D21S1440 .73
NOTE.—Underlining indicates markers with maximum two-point LOD in regions
with multipoint LOD 11.5.
a Location is in relation to p-ter.
must be observed for a family to contribute to the FBAT
statistic when parental genotypes are not available. The
statistical theory of conditioning on the sufficient sta-
tistics results in correct P values (type I error rate) re-
gardless of the population admixture, patterns of miss-
ing genotypes, or genetic model (Rabinowitz and Laird
2000).
In the present study, bothmultiallelic and biallelic tests
were performed. For the biallelic tests, an additive ge-
netic model was assumed, with Xij coded as described
above. Coding of Xij for multiallelic tests are described
elsewhere (Horvath et al. 2001). The unknown under-
lying genetic model may determine which test, biallelic
or multiallelic, is more powerful; hence, both were con-
sidered here. Two definitions of the trait were employed.
In the first definition, Tij p age at onset for offspring j
in family i. In the second definition, T p (onset ageij
, where m is a constant that is chosen to minimize them)
variance of the test statistic (Horvath et al. 2001). Age
at onset was coded as “missing” for all unaffected in-
dividuals. For these trait definitions, a positiveZ statistic
indicates that the allele is associated with later onset of
PD. In addition, the empirical variance option in FBAT
was applied, to test the null hypothesis of no association
in the presence of linkage, because associationwas tested
only in those regions showing evidence of linkage
( ) in the genome scan.LOD 1 1.5
Results
Mean age at onset for the individuals with PD who were
included in the genome scan was years60.4 11.79
(range 26–88). The skewness and kurtosis for age at
onset were .45 and .09, respectively. These values
are consistent with a normal distribution and indicate
that the normality assumptions underlying the variance-
component linkage analysis are not being violated. Al-
though age at onset was slightly higher for males
( ; ) than females ( ;61.2 11.16 np 126 59.2 12.59
), this difference was not significant ( ).np 89 Pp .23
Variance-component linkage analysis revealed four
chromosomal regions that yielded multipoint LOD
scores 11.5 (fig. 1). Maximum multipoint LOD scores
(MaxLOD) 12.0 were observed for three of these
regions, on chromosomes 2 ( at 99MaxLODp 2.08
cM), 9 ( at 116 cM), and 21MaxLODp 2.00
( at 32 cM). In addition, a MaxLODMaxLODp 2.21
of 1.82 was observed at 54 cM on chromosome 20.
Table 1 gives two-point LOD scores for the marker
yielding the maximum two-point LOD score and for its
flanking markers in these peak regions.
Tests of association with age at onset were performed
for the markers in the four regions described in table
1. No significant association was detected using the
global multiallelic test. Diallelic tests were also per-
formed, to evaluate association with specific alleles.
There were three markers, shown in table 2, for which
specific alleles showed significant evidence of associa-
tion consistently across the two tests considered (see the
“Methods” section). As shown in table 2, the number
of families that were informative for a particular test
was small, because of the low frequency of a specific
allele in a highly polymorphic microsatellite marker.
Genotyping in a larger set of affected relative pairs
was performed for the marker D2S1394. The two-point
LOD score for D2S1394 increased from 0.50 to 0.58
with the addition of 49 affected sibling pairs. In the
larger sample, there were 34 families that were infor-
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Table 2
Diallelic Family-Based Association Tests Yielding a Nominal
P ! .05.
MARKER ALLELE
P VALUE
NO. OF
FAMILIES
Empirical
Variance
Minimized
Variance
D2S1394 174 .045 .017 18
D20S477 242 .049 .049 10
D21S2052 120 .027 .023 18
Figure 2 Overlay of multipoint LOD-score curve assessing link-
age to PD affection status and to PD age at onset for chromosome 9.
mative for evaluating association between the 174 allele
and age at onset of PD. Significant association was ob-
served in this larger sample when either the empirical
variance test ( ) or the minimized variance testPp .017
( ) was used. The test statistic computed byPp .036
FBAT ( , using empirical variance) was posi-Zp 2.40
tive, indicating that later age at onset was associated
with the 174 allele in the family-based test. Examination
of age at onset among all individuals with PD revealed
that mean age at onset was similar for individuals with-
out a 174 allele ( ; ) compared61.1 12.03 np 307
with those with one 174 allele ( ; ).60.6 12.28 np 70
Age at onset was greater for 174 homozygotes
( ), although the frequency of these individ-69.8 8.75
uals was low ( ).np 5
Discussion
Segregation analysis in PD has implicated the presence
of a gene influencing age at onset of PD (Maher et al.,
in press). We performed a genomewide scan using 103
multiplex families from theGenePD study and identified
four regions with suggestive evidence of linkage to age
at onset. Two of these regions, on chromosomes 2p13
and 9q, have previously been implicated in linkage stud-
ies examining PD affection status (Gasser et al. 1998;
Scott et al. 2001). Given the limited support for addi-
tional studies, we chose to concentrate on chromosome
2p13 for follow-up in a larger sample.
The strongest evidence of linkage to age at onset (two-
point ) in our original sample was observedLODp 2.4
at 99 cM on chromosome 2, which coincides with the
location of PARK3. Affected individuals from families
that show linkage to PARK3 appear clinically similar
to individuals with idiopathic PD, although dementia
was observed in several affected individuals (Gasser et
al. 1998). Mean age at onset for PD in these families
that show linkage to PARK3 was 59 years (Gasser et
al. 1998), which is comparable to the mean age reported
here. Two North American families that show linkage
to PARK3 trace their ancestry to a common region of
southern Denmark and northern Germany and share a
common haplotype over a 2.5-Mb region, which nar-
rows the location of the PARK3 gene (West et al. 2001).
In addition to evidence of linkage, we also observed
association between the 174 allele of marker D2S1394
and age at onset. Given this association, we focused on
the D2S1394 marker when typing additional individ-
uals and observed both an increase in the LOD score
and a decrease in the P value for the test of association
to allele 174 in the augmented sample. Both the family-
based association tests and examination of mean age at
onset by genotype among all individuals with PD sug-
gest that the 174 allele is associated with a later age at
onset in this study population. Marker D2S1394 is
within the 2.5-Mb region defining PARK3, and the 174
allele is present in the PD haplotype shared by the two
families that show linkage to PARK3 (West et al. 2001).
Association of the same allele of the D2S1394 marker
in two independent studies provides strong evidence
that this allele is in linkage disequilibrium with a PD-
susceptibility gene or a gene influencing age at onset of
PD. Further studies are needed to determine the specific
gene influencing PD, variants within such a gene, and
effects of these variants. Candidate genes in this region
include transforming growth factor-a (TGFA), cyto-
chrome P450 retinoid metabolizing protein (P450RAI-
2), sepiapterin reductase (SPR, or 7,8-dihydrobiopterin:
NADP oxidoreductase), and the putative N-acetyl-
transferase Camello 2 (CML2). In addition, a number
of as-yet-undiscovered genes are predicted in this region
of linkage.
The linkage peak for age at onset on chromosome 9
overlaps with the previously reported linkage for affec-
tion status in the GenePD sample (DeStefano et al.
2001), although the peaks do not coincide, as shown
in figure 2. There are no obvious candidate genes at this
location.
Evidence of linkage to PD age at onset was also ob-
served on chromosomes 20 (multipoint )LODp 1.82
and 21 (multipoint ) in regions that haveLODp 2.21
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not been implicated in other PD linkage studies. Can-
didate genes in the region of linkage on chromosome
20 include induced transcription factor 2-b (TGIF2),
neuronatin, and protein tyrosine phosphatase receptor
T. Candidate genes on chromosome 21 include amyloid
b (A4) precursor protein and ubiquitin-specific protease
16. Evidence of association was observed for one allele
in each region. Additional studies are planned, to ex-
amine these regions more closely.
Susceptibility to a disease and age at onset of a disease
are two distinct but related phenotypes. It is possible
that separate genes may contribute to each of these as-
pects of genetic vulnerability to disease or that a gene
may influence both risk for disease and age at onset.
We have identified four regions that show suggestive
evidence of linkage to age at onset of PD. Follow-up
analysis on chromosome 2 strengthened evidence for
linkage. This region overlaps with a locus previously
implicated in studies of linkage with affection status.
Association with a specific allele on 2p13 suggests close
proximity to the gene, and additional work is ongoing,
in the GenePD and other studies, to identify the gene
at this location.
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